application) The broad long-term objectives of this project are to gain a greater understanding of the biology of iron absorption (uptake and transfer) with a view to the development of novel therapeutic approaches to iron overload diseases. Recent exciting discoveries including the hemochromatosis gene HFE and the metal transporters DMT1, hephaestin and SFT have provided the opportunity to study the steps in the pathway of iron uptake and transport across the intestinal cell as well as intracellular signaling pathways involved. In the first instance it is proposed to examine the distribution of both HFE mRNA and proteins in normal individuals, patients with hemochromatosis, other forms of iron overload and iron deficiency as well as in several animal models. In addition, this project will investigate the distribution and expression of DMT1, hephaestin, Ireg1 and SFT in these human subjects and animal models. These studies will be integrated with a more detailed analysis of HFE trafficking and processing, including the precise nature of the assembly, localization, transport and degradation of the HFE molecule. This knowledge will provide an avenue for the development of therapeutics aimed at increasing the secretion and transport of the mutated form of HFE to the compartment where it is active. The experiments in the various animal models should allow the elucidation of the relative contributions of brush border uptake and basolateral transfer in normal and abnormal iron homeostasis and the responses to various stimuli known to modulate iron absorption. A novel aspect of the experimental protocol involves hepatocyte transplantation to examine the role of the liver in regulating iron absorption. A major aspect of this study is the determination of the three dimensional structure of hephaestin and DMT1 and to use these in structure based design studies to develop novel therapeutic agents that inhibit intestinal iron absorption. Such agents will be particularly applicable to the treatment of disorders in which iron absorption is elevated, such as hemochromatosis and thalassemia. In the former this should reduce or even abolish the requirement for prolonged phlebotomy therapy which is time-consuming, expensive and often poorly tolerated by patients. The approach is a multidisciplinary one combining the expertise of members of the Clinical Sciences Unit of QIMR in iron metabolism with that of x-ray crystallography and structure-based drug design studies at the Centre for Drug Design and Development in the University of Queensland.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK057648-04
Application #
6607577
Study Section
Special Emphasis Panel (ZDK1-GRB-1 (J2))
Program Officer
Doo, Edward
Project Start
2000-09-30
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
4
Fiscal Year
2003
Total Cost
$150,000
Indirect Cost
Name
Queensland Institute of Medical Research
Department
Type
DUNS #
758815328
City
Herston
State
Country
Australia
Zip Code
4006
Ruddell, Richard G; Hoang-Le, Diem; Barwood, Joanne M et al. (2009) Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 49:887-900
Musso, Giovanni; Gambino, Roberto; Pacini, Giovanni et al. (2009) Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 49:426-35
Walsh, Alissa; Dixon, Jeannette L; Ramm, Grant A et al. (2006) The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 4:1403-10
Powell, Lawrie W; Dixon, Jeannette L; Ramm, Grant A et al. (2006) Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 166:294-301
Wallace, Daniel F; Jones, Marc D; Pedersen, Palle et al. (2006) Purification and partial characterisation of recombinant human hepcidin. Biochimie 88:31-7
Wallace, D F; Browett, P; Wong, P et al. (2005) Identification of ferroportin disease in the Indian subcontinent. Gut 54:567-8
Powell, Lawrie W; Dixon, Jeannette L; Hewett, David G (2005) Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol 18:221-34
Ramm, Grant A; Ruddell, Richard G (2005) Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 25:433-49
Wallace, Daniel F; Dixon, Jeannette L; Ramm, Grant A et al. (2005) Hemojuvelin (HJV)-associated hemochromatosis: analysis of HJV and HFE mutations and iron overload in three families. Haematologica 90:254-5
Wallace, D F; Summerville, L; Lusby, P E et al. (2005) First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 54:980-6

Showing the most recent 10 out of 16 publications